ADC Therapeutics (ADCT) Assets Average (2023 - 2026)

ADC Therapeutics has disclosed Assets Average across 4 years of filings, most recently posting $307.3 million for Q1 2026.

• Assets Average for Q1 2026 came in at $307.3 million, up 3.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $307.3 million (up 3.39% YoY), and the FY2025 annual result was $322.6 million, down 4.67% from the prior year.
• Assets Average came in at $307.3 million for Q1 2026 at ADC Therapeutics, roughly flat from $306.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.2 billion in Q2 2023 to a low of $297.0 million in Q2 2025.
• The 4-year median for Assets Average is $335.5 million (2024), against an average of $486.4 million.
• Across the five-year window, Assets Average plunged 71.69% in 2024 and rose 3.39% in 2026, its largest moves.
• ADC Therapeutics' Assets Average stood at $486.4 million in 2023, then slumped by 31.01% to $335.5 million in 2024, then retreated by 8.67% to $306.5 million in 2025, then advanced by 0.28% to $307.3 million in 2026.
• The last three Assets Average figures came in at $307.3 million (Q1 2026), $306.5 million (Q4 2025), and $305.7 million (Q3 2025), per Business Quant data.